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COMPARATIVE EFFECTIVENESS REVIEW: DRUG-ELUTING STENTS 
VERSUS BARE-METAL STENTS FOR ACUTE MYOCARDIAL INFARCTION
Suh HS1, Song H1, Choi J1, Jang E1, Son HJ2, Kim JS3, Choi DH3, Lee SM1
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 
2National Evidence-based Collaborating Agency (NECA), Seoul, South Korea, 3Yonsei 
University College of Medicine, Seoul, South Korea
OBJECTIVES: To estimate the relative impact of drug-eluting stents(DES) versus 
bare-metal stents(BMS) on death, myocardial infarction(MI), target vessel revasculari-
zation(TVR), and stent thrombosis(ST) in patients with ST-elevation acute myocardial 
infarction(STEMI) by performing comprehensive meta-analyses of randomized con-
trolled trials(RCTs) and observational studies METHODS: We searched Ovid-
Medline, EMBASE, the Cochrane Library, and conference proceedings for articles 
comparing outcomes between DES and BMS among STEMI patients presented 
through September 2009. The quality of studies was evaluated by using the Cochrane’s 
risk of bias for RCTs and MINORS(Methodological Index for Non-Randomized 
Studies) for observational studies. The relative risk(RR) using the inverse variance 
random-effects method for each study outcome was calculated. RCT and observa-
tional data were analyzed separately. To assess heterogeneity of RRs across trials, we 
used the Cochrane-Q-statistic and I2-statistic. Subgroup-analyses were performed by 
length of follow-up and meta-regression was used to evaluate predictors of outcomes 
by stent-type. Funnel plots, the Egger-test, and the Begg-test were used to assess 
publication-bias. To assess the quality of the evidence, we used GRADEpro.RESULTS: 
Fifteen RCTs were identiﬁed(N = 7654, kappa-statistic = 0.90). Compared with BMS, 
DES signiﬁcantly reduced TVR(RR:0.48; 95% conﬁdence interval[CI]:0.41–0.56) and 
MI(RR:0.76; 95%CI:0.60–0.96), without increasing death(RR = 0.88; 95%CI:0.70–
1.11) and ST(RR:0.93; 95%CI:0.72–1.21). Among 35 observational studies(N = 
44,849), DES signiﬁcantly reduced death(RR:0.85; 95%CI:0.79–0.91) and 
TVR(RR:0.61; 95%CI:0.48–0.77). MI and ST were signiﬁcantly lower in the DES 
group within 1-year follow-up, but there were no differences within 2-years follow-up. 
There was no evidence of statistical heterogeneity and publication-bias. Among RCTs, 
the quality of the evidence of TVR was assessed as “High”, death and MI as “moder-
ate”, and ST as “low”. The quality of the evidence from observational studies was 
assessed as “very low” or “low”. CONCLUSIONS: These data in aggregate suggest 
that using DES in STEMI patients are safe and efﬁcacious but there are differences 
between RCT and observational data comparing DES and BMS.
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BELIEFS ABOUT ANTIHYPERTENSIVE MEDICATIONS IN PRIMARY 
CARE PATIENTS: VALIDATION OF BELIEFS ABOUT MEDICINES 
QUESTIONNAIRE (BMQ) IN COLOMBIA
Garcia Vega OA, Buendia Rodriguez JA
Universidad Nacional de Colombia, Bogota, Colombia
OBJECTIVES: determinate the factor structure of the Beliefs about Medicines Ques-
tionnaire (BMQ) and examine the association of medication beliefs with medication 
adherence METHODS: Seventeen patients who used antihypertensive drugs partici-
pated in semi-standardized interviews. Interviews were recorded and reviewed by two 
investigators. The medication adherence was measured using the method of count of 
tablets. An exploratory factor analysis was performed. Multiple linear regression was 
used to determine whether beliefs about medications were signiﬁcantly associated with 
medication adherence RESULTS: Factor analysis resulted in a two solution, explaining 
46.7% of cumulative variance among respondents. The factors were labeled: Overuse 
(Concerns about the way doctors use medications) and Harm (Beliefs that medications 
are harmful). Chronbach’s alpha coefﬁcient was 0.71. Beliefs about medications 
(Overuse and Harm) were signiﬁcantly associated with non-adherence to antihyper-
tensive drugs CONCLUSIONS: The factorial structure of BMQ was similar than 
previously reported in other medical conditions. Also these ﬁndings suggest that in 
addition to telling patients how to take their medications, primary care physicians 
should educate patients about short and long-term effects of the medication and all 
possible therapeutic alternatives to improve the adherence to antihypertensive 
medication.
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DERIVING DOCTORS’ PRESCRIBING PATTERNS FROM CLAIMS DATA: 
AN APPLICATION TO ANTICOAGULANT USE IN PATIENTS WITH 
NON-VALVULAR ATRIAL FIBRILLATION
Wang L1, Gust C1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research / University of 
Michigan, Ann Arbor, MI, USA
OBJECTIVES: Doctors’ practice and prescribing patterns are based on many factors, 
some of which are not observable. We derived doctors’ prescribing patterns from U.S. 
claims data to show how it might be related with decisions on anticoagulant use for 
venous thromboembolism (VTE) treatment. METHODS: Based on U.S. claims data, 
we assigned doctors IDs based on the physician who treated the enrollee for the longest 
period of time after eliminating any emergency room, laboratory, and radiology ser-
vices. Physician prescribing patterns were then calculated from prescription drug 
records. Patients were grouped as compliant and non-compliant to warfarin. 
RESULTS: We identiﬁed the doctors’ prescribing pattern with the percentage of time 
they prescribed warfarin, injectable anticoagulation, antiplatelet, anti-arrhythmics, 
rate control drugs and other drugs. We showed that patients were more likely to be 
compliant to warfarin if their physician’s prescribing pattern favored warfarin. 
Patients were less compliant if their physician’s prescribing pattern favored injectable 
anticoagulation or antiplatelet. There were no effects on compliance if doctors’ pre-
scribing patterns favored anti-arrhythmics or rate control drugs. CONCLUSIONS: 
Doctors’ prescribing patterns are important factors for patient compliance. Therefore, 
failing to control for these patterns in compliance models might lead to omitted vari-
able bias.
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IMPACT OF A SEMINAL STUDY ON PRACTICE PATTERNS: STATIN USE 
BEFORE AND AFTER THE JUPITER STUDY
Cload P1, Kallenbach L2, Ross S3, Haas S4, Gunnarsson C5
1GE HealthCare, Chalfont St Giles, Bucks, UK, 2GE Healthcare IT, Clinical Data Services, 
Plano, TX, USA, 3SDRoss Consulting, Cohasset, MA, USA, 4S2 Statistical Solutions, Inc., 
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OBJECTIVES: To examine whether there was a change in statin use patterns after 
release of results from the JUPITER study using a nationally-representative Electronic 
Medical Record (EMR) database. METHODS: The EMR database reviewed was the 
Medical Quality Improvement Consortium (MQIC) database from GE. This database 
contains EMR data collected from over 11,000 ambulatory providers in the United 
States and includes over 12 million patients as of April, 2009. Records were reviewed 
for the total database before and four months after. Among adults ≥ 18 years of age, 
new statin usage (4 months before and after) and switches involving rosuvastatin, the 
statin in the JUPITER study, were counted. RESULTS: Of over 9.4 million adults, 
over 1.2 million (13%) are recorded as taking a statin. The proportion of statin usage 
remained consistent before and 4 months after JUPITER with percentage of use among 
the patients as follows: rosuvastatin (11%), simvastatin (32%), atorvastatin (49%), 
other statins (27%), or a recently approved statin/ezetimibe (11%) combination 
product (percents add to more than 100 as patients may be on more than one product). 
When comparing the proportion of reported new statin usage 4 months pre/post 
JUPITER among the new statin users, there is an increase in simvastatin, from 26% 
to 29%, with other statins showing slight decreases in that time period. CONCLU-
SIONS: Although JUPITER is already considered a seminal study by many, it has not 
yet impacted clinical practice, suggesting a time lag in getting evidence into practice. 
This EMR database provides a valuable data source to monitor real-time, real-world 
prescribing practices, and will permit further exploration of relevant patient charac-
teristics, such as CRP and LDL levels, and outcomes that is not possible using admin-
istrative datasets.
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STATIN USE BEFORE AND AFTER CABG PROCEDURE
Iyer RG, Matlin O
CVS|Caremark, Northbrook, IL, USA
OBJECTIVES: Statin therapy has been shown to reduce disease progression following 
coronary artery bypass graft procedure (CABG). Recommendations include low-fat 
diet and cholesterol-lowering medications after bypass surgery to reduce subsequent 
graft attrition. The objectives of the study were to 1) examine the percent of par-
ticipants who were prescribed a statin within a month post CABG procedure 2) 
identify predictors of statin use post CABG METHODS: Participants with CABG 
anytime during 2003–2008 and their statin use pre-post CABG were identiﬁed using 
de-identiﬁed administrative medical claims and administrative pharmacy claims 
respectively. Date of CABG was considered the index date for the study analysis. 
The variables to predict a new script for statin included use of statin before CABG, 
age, gender, physician specialty, other co-morbidities, and the number of other 
medications. A logistic regression was used to estimate the likelihood of statin uti-
lization post CABG. RESULTS: The study cohort consisted of 10,418 patients who 
underwent CABG during the study period. The mean age of the cohort was 70.3 
± 11.2 years, and 75% of the patients were male. During the 1-year period before 
CABG surgery, 40% of patients utilized prescription statin therapy. 47% of patients 
ﬁlled a statin prescription within 1 month of CABG procedure. 24% of the patients 
did not have prescription claims for statins any time post CABG. The likelihood of 
ﬁlling a prescription for statin post CABG was 5.51 (95% CI: 4.89–6.21) higher in 
patients who utilized a statin prior to CABG. Males were 1.36 times more likely 
to utilize a statin than females (95% CI: 1.22–1.51) CONCLUSIONS: A signiﬁcant 
proportion of patients do not utilize statins after CABG, missing effective drug 
therapy. The use of statin before CABG is a signiﬁcant predictor of statin use 
post-CABG.
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NOVEL QUALITY ASSURANCE ANALYSIS REVEALS PREVIOUSLY 
UNDETECTED DEFICIENCIES IN A POINT OF CARE DEVICE THAT 
MEASURES THE INTERNATIONAL NORMALIZED RATIO
Shermock KM1, Pinto BL1, Streiff MB2, Lavallee DM3
1The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 2The Johns Hopkins University 
School of Medicine, Baltimore, MD, USA, 3Lovelace Respiratory Research Institute, Sykesville, 
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OBJECTIVES: Measures used to make clinical decisions are assessed by quality assur-
ance (QA) programs. Our group’s research suggests standard QA analyses can fail to 
provide relevant clinical information and may be misleading. We compared a novel 
clinically-based QA analysis to previously conducted standard QA analysis of INR 
measures by point-of-care (POC) devices in our anticoagulation clinics. METHODS: 
Previously analyzed QA data, collected January, 2006 through June, 2008 were 
obtained. Two INR samples were obtained from each patient at the same anticoagula-
tion clinic visit: one venous sample analyzed by our core laboratory (considered the 
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reference measure) and one ﬁngerstick analyzed by the Hemochron POC device. 
Consistent with published FDA recommendations, the previous standard QA analysis 
included linear regression, correlation and Bland Altman analysis. The novel QA 
analysis features thorough descriptive analysis and a validated method to estimate 
when INR measures lead to the same clinical decision. RESULTS: 1,666 paired INRs 
were collected. Standard QA analysis deemed the Hemochron device acceptable. 
Notably, the correlation between the Hemochron and laboratory was 0.9. Our novel 
analysis revealed the Hemochron never reported seven INR values: 2.1, 2.7, 3.1, 3.5, 
3.8, 4.1, and 4.4. Furthermore, the Hemochron systematically inﬂated lower INRs 
and deﬂated higher values. Consequently, 30% (503 / 1,666) of clinical decisions were 
predicted to differ using the Hemochron. The laboratory was nearly twice as likely to 
report an INR below the target range (RR: 1.9, 95% CI: 1.7–2.1) than the Hemo-
chron. CONCLUSIONS: Standard QA analysis missed clinically important deﬁcien-
cies in the Hemochron device. Our novel analysis revealed the Hemochron does not 
report all INR values and leads to incorrect clinical decisions an unacceptably large 
proportion of times. The Hemochron device has been replaced in our institution. QA 
analyses should be reported in explicitly clinical terms so decision-makers understand 
the implications to patient care.
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RELATIONSHIP BETWEEN VENOUS THROMBOEMBOLISM AND 
HOSPITAL QUALITY
Baser O1, Akin C2, Wang L3, Dysinger A3
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research / Brigham and Women’s Hospital, Ann Arbor, MI, USA, 3STATinMED Research, 
Ann Arbor, MI, USA
OBJECTIVES: To examine the association between venous thromboembolism (VTE) 
events and hospital quality for patients who underwent major orthopedic surgery. 
METHODS: Based on 2005–2007 national Medicare claims, all patients who under-
went major orthopedic surgery were identiﬁed. Rates for patients who had a VTE 
event during their initial hospitalization were calculated. By using the CompQualTM 
scoring algorithm, every provider in the Medicare dataset was ranked according to 
their quality. This algorithm, with an empirical Bayesian approach, combines volume 
and mortality rate of hospitals to create an index score. Hospitals are ranked in 
quintiles. Logistic regression was used to see the effect of quality on VTE event rates. 
RESULTS: We obtained a sample that included 642 patients in the pulmonary embo-
lism (PE) only group, 1950 patients in the deep vein thrombosis (DVT) only group, 
and 153 patients in the both PE and DVT group. After controlling for patients’ 
demographic and clinical factors, VTE events in low quality hospitals were almost 2.5 
times higher than VTE events in high quality hospitals (p = 0.000). CONCLUSIONS: 
Any policy implementation that would decrease the variation in hospital quality would 
have a direct effect on the rates of VTE events.
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QUALITY OF PHARMACEUTICAL CARE PROVIDED IN A CHRONIC 
DISEASE: GEOGRAPHIC VARIATION, PROCESS OF CARE MEASURES 
AND CLINICAL OUTCOMES
Johnson ML, Agarwal S, Aparasu R, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: To determine association of recommended pharmacotherapy in CHF 
with geographic variation in clinical outcomes. METHODS: Veterans with at least 
one outpatient visit with CHF diagnosis from FY2000–2001 were included in a 
cohort. Patients with non-utilization of VA for two years were excluded. Twenty-two 
Veteran Integrated Service Network (VISNs) of the VA were geographic units of 
analyses. Outcomes evaluated were: death, all-cause hospitalization and heart failure 
hospitalization. Recommended pharmacotherapy was measured by use of ACE inhibi-
tors, ARBs and Beta-blockers. Follow up period was one year post index date of CHF 
diagnosis. We accounted for patient factors (gender, race, age, co-morbidities, severity 
of illness, co-medications, adherence) and process of care measures (prescription of 
recommended pharmacotherapy). Multivariate logistic regression models were used 
to calculate observed-to-expected (O/E) ratios across VISNs. Separate models were 
constructed accounting for patient factors, process of care measures and structure 
(VISNs). We ranked the outliers and interpreted, in context of, the quality of phar-
maceutical care provided. RESULTS: We analyzed 125,239 CHF cases with enough 
power to detect differences across VISNs. About 60% patients were on ACE inhibi-
tors, 8% on ARBs and 49% on Beta Blockers. Factor of variance in prescription rates 
ranged from 1.11 to 2.79. Strong correlation was observed between prescription rates 
and outcome rates (−0.48 to −0.54). c-indexes for all the models were above 0.7. 
Change in the outlier status, from the model containing patient factors versus the 
model with patient factors and process of care factors, indicated change in the quality 
of pharmaceutical care provided by the VISNs. CONCLUSIONS: In 1998, VA imple-
mented Quality Enhancement Research Initiative (QUERI) to systemize quality 
improvement. During FY2000–02, signiﬁcant variations were observed in prescription 
and outcome rates, despite efforts to synchronize quality of care. Differential prescrip-
tion rates and differential adherence rates led to the variations in the outcomes.
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UTILIZATION OF SECONDARY PREVENTIVE MEDICATIONS 
FOLLOWING ACUTE MYOCARDIAL INFARCTION (AMI): A 
RETROSPECTIVE COHORT ANALYSIS OF A MEDICAID POPULATION
Mulvaney J1, Kalsekar I1, Koehler J1, Chavis R2, Stitz L3
1Butler University, Indianapolis, IN, USA, 2Union Hospital, Terre Haute, IN, USA, 3CVS 
Pharmacy, Flora, IL, USA
OBJECTIVES: To assess the utilization of secondary preventive medications after an 
acute myocardial infarction (AMI) in a state Medicaid population. METHODS: The 
study was a retrospective cohort analysis using a state Medicaid claims database. The 
study cohort was identiﬁed based on inpatient claims for discharges with either a 
primary or secondary diagnosis code for AMI (ICD-9 code: 410.XX) between January 
1, 2002 and December 31, 2006. The study cohort was restricted to patients who 
were < 65 years old and were enrolled in the traditional fee-for-service program. 
Utilization of secondary preventive medications was considered appropriate if patients 
ﬁlled at least 1 prescription for each of the recommended medications (angiotensin-
converting enzyme (ACE) inhibitors /angiotensin-receptor blockers, beta-blockers, and 
statins) in the 90 days after discharge. Logistic regression analysis was used to identify 
demographic and clinical predictors associated with the recommended utilization of 
secondary preventive medications. RESULTS: The ﬁnal study cohort consisted of 752 
patients discharged following hospitalization for AMI. The mean age of the cohort 
was 53±7.9 years and there were a higher proportion of females (59%) and whites 
(84.6%) in the study sample. Only 43.25% of the patients appropriately utilized all 
the recommended medications after AMI. Regression analysis indicated that use of 
percutaneous transluminal coronary angioplasty (PTCA) procedures during the hos-
pitalization (OR = 2.64; 95% CI:1.78–3.89); having a diagnosis of hyperlipidemia 
(OR = 1.71; 95% CI:1.17–2.51), hypertension (OR = 2.00; 95% CI:1.18–3.39) or 
asthma (OR = 0.56; 95% CI:0.37–0.87); and utilization of the recommended medica-
tions prior to hospitalization (OR = 2.42;95% CI:1.30–4.50) were signiﬁcant predic-
tors of appropriate utilization of secondary preventive medications. CONCLUSIONS: 
Post-AMI patients in a state Medicaid program had sub-optimal utilization of second-
ary preventive medications; however, the utilization rates were higher than in previous 
studies that primarily focused on an older cohort of patients.
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ASSESSMENT OF MEDICATION UTILIZATION PATTERN OF PATIENTS 
WITH SYSTOLIC HYPERTENSION AND COMPELLING INDICATIONS IN 
A PRIMARY CARE PRACTICE
Ombengi DN1, Kamal KM1, Civitarese L2, Rihn T1, Mattei TJ1
1Duquesne University, Pittsburgh, PA, USA, 2Primary Care Physicians, Pittsburgh, PA, USA
OBJECTIVES: The study evaluated medication utilization pattern of patients aged 50 
years and older with systolic hypertension (SH) in a primary care setting. Speciﬁc 
objectives were: 1) to assess the prevalence of comorbid conditions by patient demo-
graphics, and 2) to study the utilization of antihypertensive classes based on compel-
ling indications. METHODS: Retrospective analysis was conducted using GE 
Centricity electronic medical records (EMR) from a large primary care physician 
group. Patients with SH (ICD-9-CM 401.xx) with systolic blood pressure (SBP) 
>140 mmHg, diastolic blood pressure (DBP) <90 mmHg, 50 years and older, continu-
ously enrolled in the database and having 12 months pre- and post-index date observa-
tions were identiﬁed. Patients on dialysis were excluded from the study. Demographics, 
ofﬁce visits, clinical measures, compelling indications for antihypertensive treatment 
and comorbidities, drug regimens over a 2-year period were collected. Descriptive 
analysis was performed using SPSS version 17. RESULTS: A total of 22,074 patients 
had hypertension out of which 1,616 met the inclusion/exclusion criteria for SH. Mean 
age was 68.88±11.38 years; 59.03% females, and 78.4% had one or more compelling 
indications/comorbidities. Hyperlipidemia was the most prevalent comorbid condition 
(70.9%, n = 1,145), followed by diabetes (24.7%, n = 399) and coronary artery disease 
(15.6%, n = 252). A total of 16.4% of SH patients were on statins, followed by CCBs 
(16.2%) and ACEIs (15.3%). By compelling indications (top medication class), 18.8% 
patients with diabetes were taking CCBs, 16.9% patients with hyperlipidemia were 
taking CCBs, and 15.8% patients with CAD were taking ACEIs. CONCLUSIONS: 
Evidence from large clinical trials demonstrate that appropriate use of antihypertensive 
therapy in patients with SH and compelling indications reduces the incidences of 
stroke, myocardial infarction, and heart failure. Thus, it is important for physicians 
to follow the Seventh Joint National Committee (JNC 7) guidelines to improve quality 
of care and health outcomes in patients with SH.
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TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS OF 
PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN THE US
Angalakuditi M1, Buysman E2, Bancroft T2, Beardsworth A1
1Eli Lilly & Co, Indianapolis, IN, USA, 2I3 Innovus, Eden Prairie, MN, USA
OBJECTIVES: Oral therapies that target nitric oxide signaling (sildenaﬁl) or endothe-
lin signaling (bosentan and ambrisentan) are used to treat pulmonary arterial hyper-
tension (PAH). We studied the treatment patterns, resource utilization, and costs 
associated with these three oral therapies in a US population of commercially insured 
patients. METHODS: This was a retrospective study using claims from a large health 
insurance database. Commercial and Medicare Advantage patients with claims indi-
cating PAH between January 2006 and December 2008 and whose ﬁrst PAH treat-
ment was for ambrisentan, bosentan, or sildenaﬁl were selected for study inclusion. 
PAH treatment patterns, PAH-related utilization, and PAH-related costs were assessed 
during a minimum 6 month follow-up period. RESULTS: A total of 727 patients were 
